Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Surface Oncology Highlights New SRF388 Data At AACR Meeting

Surface Oncology Inc (NASDAQ:SURF) announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research (AACR) Annual Meeting 2022.

  • Pharmacokinetics (PK) from the dose-escalation phase of the SRF388 Phase 1 study were linear, with no dose-limiting toxicities reported.
  • The concentration of SRF388 associated with optimal antitumor activity in a preclinical mouse model was approximately 20-fold above the concentration needed to inhibit whole blood phosphorylated STAT1 completely.
  • The concentration of SRF388 was reached and exceeded in patients at a 10 mg/kg dose. One patient with squamous non-small-cell lung cancer experienced a confirmed partial response at this dose.
  • SRF388 translational data supports the recommended Phase 2 monotherapy dose selection of 10 mg/kg administered intravenously every four weeks.
  • The efficacy of adding IL-27 blockade with SRF388 to atezolizumab/bevacizumab in treatment-naïve HCC is also being explored in a Phase 2 study.
  • Price Action: SURF shares are down 2.17% at $2.71 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.